Failed tubulin inhibitor reformulated as localized adjuvant therapy for head and neck cancer
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261201600028C
- Awardee
-
Qrono, Inc. UEI S8NSYCMSNF79
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,496,236
Award facts
- Opportunity
-
- BAAN44CO6700679 Solicitation number
- Contract value 100% obligated
- $1,496,236.49 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Pittsburgh, PA 15213, USA
- Research
- SBIR Program Phase II Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$2,016 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,498,252 |
About this award
This $1,496,236.49 federal contract was awarded by the National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, to Qrono, Inc., a small business. The contract is focused on reformulating a failed tubulin inhibitor as a localized adjuvant therapy for head and neck cancer. This Phase II Small Business Innovation Research (SBIR) contract involves developing a novel drug delivery system and immunotherapy approach to address this medical challenge. Qrono, Inc. is an experienced medical research and development company that has secured multiple contracts and grants from federal agencies, including the National Institute of Allergy and Infectious Diseases, to advance innovative therapeutic interventions targeting specific cellular mechanisms.
Quick answers
Who was awarded contract HHSN261201600028C?
HHSN261201600028C was awarded to Qrono, Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2016.
How much is contract HHSN261201600028C worth?
The government has obligated $1,496,236 on HHSN261201600028C.
Was contract HHSN261201600028C competed?
The extent of competition for HHSN261201600028C was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award